Related Experiment Video
Updated: Aug 21, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Headache Caused by Giant Cell Arteritis
Thomas N Ward1, Morris Levin, Robert L Wong
1Section of Neurology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA. Thomas.N.Ward@hitchcock.org.
Insights
Giant cell arteritis (GCA) is a common vasculitis in those over 50. Early diagnosis and prompt treatment are crucial to prevent serious complications like blindness and stroke, despite potential steroid side effects.
Area of Science:
- Rheumatology
- Internal Medicine
- Vasculitis
Background:
- Giant cell arteritis (GCA) is the most frequent primary systemic vasculitis affecting individuals over 50.
- Common symptoms include headache (90%), but serious complications like blindness and stroke can occur without it.
- Nonspecific symptoms like weight loss, fever, and malaise can also dominate the clinical picture.
Purpose of the Study:
- To review the clinical presentation, diagnosis, and management of Giant Cell Arteritis (GCA).
- To highlight the importance of prompt diagnosis and treatment to prevent severe outcomes.
- To discuss current therapeutic strategies and emerging treatment options for GCA.
Main Methods:
- Review of clinical characteristics of GCA.
- Discussion of diagnostic criteria and laboratory findings (ESR > 50 mm/h).
- Analysis of current treatment protocols, including corticosteroids and steroid-sparing agents.
Main Results:
- Corticosteroids are the primary treatment, initiated promptly upon suspicion.
- Relapses are common, and steroid side effects are a significant concern in the elderly.
- Steroid resistance necessitates alternative or adjunctive therapies.
Conclusions:
- Prompt initiation of corticosteroids is vital for managing GCA and preventing complications.
- Emerging evidence suggests efficacy of anti-TNF-alpha agents as steroid-sparing options.
- New or worsening headaches in patients over 50 warrant immediate GCA evaluation and management.
Abstract:
Giant cell arteritis (GCA) is the most common primary systemic vasculitis in older adults. Patients usually are older than 50 years and have an erythrocyte sedimentation rate (Westergren) greater than 50 mm/h. Headache is a common symptom, occurring in approximately 90% of patients. However, the most serious complications of GCA, blindness and stroke, may occur in the absence of headache. Nonspecific constitutional symptoms such as weight loss, fever, and malaise may dominate the clinical presentation. Currently, corticosteroids are the mainstay of therapy for GCA. Treatment is initiated at 0.7 to 1 mg/kg mg of prednisone (or equivalent) per day as soon as the diagnosis is suspected. The medication is tapered based on laboratory parameters and symptoms. Relapse is common, especially during the first year of therapy. Side effects from steroids in the elderly are common and often serious. Steroid resistance (manifesting as continued high dose requirements after 3 to 6 months) may complicate therapy and place patients at increased risk of side effects. Methotrexate and azathioprine have been used as steroid-sparing agents based on anecdotal evidence. More recently, evidence is emerging that antitumor necrosis factor-alpha agents may be efficacious and act as steroid-sparing agents. New-onset headache or worsening headache in a patient older than 50 years should raise the possibility of GCA and appropriate therapeutic and diagnostic measures should be begun promptly.
Related Concept Videos
Encephalitis l: Introduction
Increased Intracranial Pressure ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Increased Intracranial Pressure l: Introduction
Arboviral Encephalitis
Angle Closure Glaucoma: Treatment
